Agilent Announces Solutions Innovation Research Award to Dr. Jiangbin Ye Agilent Announces Solutions Innovation Research Award to Dr. Jiangbin Ye Agilent Technologies Inc. (NYSE: A) announced...
Agilent Announces End-to-End Digital Pathology Workflow Solution at USCAP 2023 Agilent Announces End-to-End Digital Pathology Workflow Solution at USCAP 2023 Agilent Technologies Inc. (NYSE: A)...
Agilent’s Certified Pre-Owned Instruments Program Receives Environmental Award Agilent’s Certified Pre-Owned Instruments Program Receives Environmental Award Agilent Technologies Inc. (NYSE: A)...
Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell...
Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC) Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial...
Agilent Names John Palma to Lead Global Medical Affairs Organization Agilent Names John Palma to Lead Global Medical Affairs Organization Agilent Technologies, Inc. (NYSE: A) today...
Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric,...
Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast...
Agilent and Visiopharm Expand Collaboration with Worldwide Distribution Agreement Agilent and Visiopharm Expand Collaboration with Worldwide Distribution Agreement Agilent Technologies Inc. (NYSE: A)...
Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Esophageal Cancer Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Esophageal Cancer PD-L1 IHC 22C3 pharmDx can now...